News | September 22, 2011

HFSA Session Highlights Growing Relationship Between Cardiology and Oncology

September 22, 2011 — The 15th annual scientific meeting of the Heart Failure Society of America (HFSA) will feature a session titled "Cancer Chemotherapy and Cardiotoxicity" moderated by Daniel J. Lenihan, M.D., professor of medicine at Vanderbilt University. It will focus on the effect of cancer drugs on the presence of heart failure and how oncologists and cardiologists have developed close collaboration in order to benefit patients.

Scheduled presentations include discussions of long-term cancer care and its relation to cardiology; effects of chemotherapy on cardiotoxicity; and the effect of heart failure on therapies for cancer patients. The session highlights how physicians should treat patients and collaborate with other doctors in different areas.

"It's no longer a physician's myopic perspective when caring for a patient; we're all on the same team – the patient's team," said Lenihan. "As cardiologists engage more and more with oncologists, and vice-versa, we are not only benefiting our current patients but are also enhancing the future of modern medicine."

The session will describe the impact of chemotherapeutic agents on heart failure and will discuss recommended management options. Doctors will also discuss recent research and discoveries relating to heart failure and its connection to cancer chemotherapy.

For more information: www.hfsa.org

Related Content

Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure| October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Overlay Init